Press Release

November 29 2022

Verismo Therapeutics Establishes R&D Center in Philadelphia to Drive KIR-CAR Platform Forward

MORE >

September 28 2022

Verismo Therapeutics Receives U.S. FDA Orphan Drug Designation for SynKIR™-110, a First-in-Class KIR-CAR T Cell Immunotherapy Candidate, for the Treatment of Mesothelioma

MORE >

September 20 2022

Verismo Therapeutics Announces FDA Clearance of IND Application for SynKIR™-110, a KIR-CAR T Cell Immunotherapy Candidate

MORE >

August 19 2022

Verismo Therapeutics Announces Submission of IND Application to the FDA for SynKIR™-110, a KIR-CAR T-cell Immunotherapy Candidate

MORE >

June 21 2022

Verismo Therapeutics Announces Research Partnership with the University of Pennsylvania

MORE >

April 19 2022

Verismo Therapeutics Expands Scientific Team to Advance its KIR-CAR Platform for the Treatment of Solid Tumors

MORE >

December 15 2021

Biopharma charts progress in translating CAR-T cell therapies to solid cancers

MORE >

November 9 2021

Verismo Therapeutics Appoints Steven Albelda, MD, to Scientific Advisory Board

MORE >

October 13 2021

Verismo Therapeutics Appoints Laura Johnson, Ph.D. as Chief Scientific Officer

MORE >